VIVUS (VVUS) partially redeemed itself to shareholders yesterday after releasing impressive prescription data for its obesity drug Qsymia -- but it'll take more than that for this drug to reach blockbuster status. To make matters worse, the Belviq launch by VIVUS' rival Arena Pharmaceuticals (ARNA) is just around the corner and could put a wet towel on VIVUS' recent progress if it proves to be successful.
However, the battle for dominance in the obesity space is just getting started. Focusing on VIVUS in this video, health care analyst Max Macaluso identifies three areas that the company rapidly needs to improve if it hopes to dominate this therapeutic space.
